drugset / Trial / NCT00364455
Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.
Phase 3
Completed
56 enrolled
Janssen-Ortho Inc., Canada
Ontario Clinical Oncology Group (OCOG) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study was to evaluate the effect of treatment with epoetin alfa (recombinant human erythropoietin) or placebo on anemia related quality-of-life and anemia in hormone-refractory (not responding to hormone therapy) prostate cancer patients.
Timeline
- Start
- 2002-12
- Primary completion
- —
- Completion
- 2006-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | epoetin alfa | Protein / enzyme biologic | 40000 iu | Subcutaneous |